Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.42 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | S100A4 | P26447 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6310965 | 0.84 | TSHR (0.38) | TSHRLMNATDP1ALDH1A1GPR35 | |
| SCHEMBL3317507 | 0.84 | ALDH1A1 (0.41) | TSHRLMNATDP1ALDH1A1GPR35 | |
| SCHEMBL41321 | 0.84 | GPR35 (0.45) | TSHRLMNATDP1ALDH1A1GPR35 | |
| SCHEMBL261451 | 0.84 | TDP1 (0.45) | TSHRLMNATDP1ALDH1A1GPR35 | |
| SCHEMBL2350187 | 0.84 | TSHR (0.38) | TSHRLMNATDP1ALDH1A1GPR35 | |
| SCHEMBL9047649 | 0.79 | TDP1 (0.36) | TSHRLMNATDP1ALDH1A1GPR35 | |
| SCHEMBL8955807 | 0.79 | HSP90AA1 (0.35) | TSHRLMNATDP1ALDH1A1GPR35 | |
| SCHEMBL11204019 | 0.79 | ALDH1A1 (0.36) | TSHRLMNATDP1ALDH1A1GPR35 | |
| SCHEMBL3297299 | 0.79 | ALDH1A1 (0.41) | TSHRLMNATDP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL458793 | 0.79 | TDP1 (0.36) | TSHRLMNATDP1ALDH1A1GPR35 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1036 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118344695-A | Hydroxyl-enriched cycloolefin copolymer long afterglow material and application thereof | 重庆理工大学 | 2024-07-16 | — | — | CN | claimed |
| US-11926746-B2 | Active energy ray-curable ink and image recording method | FUJIFILM CORPORATION (JP) | 2024-03-12 | — | — | US | claimed |
| CN-114728520-B | Active energy ray-curable ink and image recording method | 富士胶片株式会社 | 2024-03-08 | — | — | CN | claimed |
| US-11555081-B2 | Multifunctional bisacylphosphine oxide photoinitiators | IGM RESINS ITALIA S.R.L. (IT) | 2023-01-17 | — | — | US | claimed |
| EP-4059719-A1 | ACTIVE ENERGY BEAM-CURABLE INK AND IMAGE RECORDING METHOD | FUJIFILM Corporation (JP) | 2022-09-21 | — | — | EP | claimed |
| CN-114989519-A | Application of cycloolefin polymer in long afterglow material | 重庆理工大学 | 2022-09-02 | — | — | CN | claimed |
| US-20210347919-A1 | MULTIFUNCTIONAL BISACYLPHOSPHINE OXIDE PHOTOINITIATORS | IGM RESINS ITALIA S.R.L. (IT) | 2021-11-11 | — | — | US | claimed |
| EP-3847179-A1 | MULTIFUNCTIONAL BISACYLPHOSPHINE OXIDE PHOTOINITIATORS | IGM Resins Italia S.r.l. (IT) | 2021-07-14 | — | — | EP | claimed |
| WO-2021095580-A1 | ACTIVE ENERGY BEAM-CURABLE INK AND IMAGE RECORDING METHOD | 富士フイルム株式会社 | 2021-05-20 | — | — | WO | claimed |
| CN-112673012-A | Multifunctional bisacylphosphine oxide photoinitiators | 意大利艾坚蒙树脂有限公司 | 2021-04-16 | — | — | CN | claimed |
| US-20060052636-A1 | Method for the production of acylphosphine oxides | BASF AKTIENGESELLSCHAFT (DE) | 2006-03-09 | — | — | US | claimed |
| US-20050260735-A1 | Method of decomposing protein with sulfonic acid compound | ARKRAY, INC. (JP) | 2005-11-24 | — | — | US | claimed |
| WO-2005105757-A1 | TRI-SUBSTITUTED UREAS AS CYTOKINE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2005-11-10 | — | — | WO | claimed |
| US-20050245555-A1 | Tri-substituted ureas as cytokine inhibitors | THE PROCTER & GAMBLE COMPANY (US) | 2005-11-03 | — | — | US | claimed |
| US-20050222294-A1 | Acyl- and bisacylphosphine derivatives | IGM GROUP B.V. (NL) | 2005-10-06 | — | — | US | claimed |
| EP-1522593-A1 | METHOD OF DECOMPOSING PROTEIN WITH SULFONIC ACID COMPOUND | ARKRAY, Inc. (JP) | 2005-04-13 | — | — | EP | claimed |
| WO-2004094439-A2 | METHOD FOR THE PRODUCTION OF ACYLPHOSPHINES | BASF AKTIENGESELLSCHAFT (DE) | 2004-11-04 | — | — | WO | claimed |
| EP-0421774-B1 | Process for production of optically active 2-(tetrahydropyran-2-yloxy)-1-propanol | TAKASAGO PERFUMERY CO LTD (JP) | 1994-06-15 | — | — | EP | claimed |
| US-5128489-A | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE 2-(TETRAHYDROPYRAN-2-YLOXY)-1-PROPANOL | TAKASAGO INTERNATIONAL CORPORATION (JP) | 1992-07-07 | — | — | US | claimed |
| US-4365082-A | CATALYTIC OXIDATION, ESTERIFICATION | INSTITUT FRANCAIS DU PETROLE (FR) | 1982-12-21 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11555081-B2 | Multifunctional bisacylphosphine oxide photoinitiators | PHOSPHO1, AGPAT5, PARG | TSHR 4231/4885LMNA 2119/4885TDP1 1123/4885 |
| US-20050245555-A1 | Tri-substituted ureas as cytokine inhibitors | IL1B, IL1A, IL6 | TSHR 3023/4885LMNA 4046/4885TDP1 1413/4885 |
| US-20210347919-A1 | MULTIFUNCTIONAL BISACYLPHOSPHINE OXIDE PHOTOINITIATORS | PHOSPHO1, AGPAT5, PARG | TSHR 4231/4885LMNA 2119/4885TDP1 1123/4885 |
| US-20060052636-A1 | Method for the production of acylphosphine oxides | AGPAT5, PNPO, PHOSPHO1 | TSHR 3990/4885LMNA 4063/4885TDP1 1967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.